As of 2024-12-15, the EV/EBITDA ratio of NextCell Pharma AB (NXTCL.ST) is -2.39. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NXTCL.ST's latest enterprise value is 100.85 mil SEK. NXTCL.ST's TTM EBITDA according to its financial statements is -42.20 mil SEK. Dividing these 2 quantities gives us the above NXTCL.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 22.5x - 29.8x | 26.2x |
| Forward P/E multiples | 21.8x - 29.7x | 25.8x |
| Fair Price | (12.33) - (16.50) | (14.34) |
| Upside | -710.2% - -916.6% | -810.0% |
| Date | EV/EBITDA |
| 2024-12-13 | -2.39 |
| 2024-12-12 | -2.30 |
| 2024-12-11 | -1.90 |
| 2024-12-10 | -2.06 |
| 2024-12-09 | -1.97 |
| 2024-12-06 | -1.97 |
| 2024-12-05 | -1.92 |
| 2024-12-04 | -1.92 |
| 2024-12-03 | -2.03 |
| 2024-12-02 | -2.01 |
| 2024-11-29 | -1.92 |
| 2024-11-28 | -1.96 |
| 2024-11-27 | -1.92 |
| 2024-11-26 | -1.82 |
| 2024-11-25 | -1.80 |
| 2024-11-22 | -1.89 |
| 2024-11-21 | -1.94 |
| 2024-11-20 | -1.89 |
| 2024-11-19 | -1.87 |
| 2024-11-18 | -1.92 |
| 2024-11-15 | -1.97 |
| 2024-11-14 | -2.01 |
| 2024-11-13 | -1.99 |
| 2024-11-12 | -2.01 |
| 2024-11-11 | -1.97 |
| 2024-11-08 | -1.90 |
| 2024-11-07 | -2.01 |
| 2024-11-06 | -1.92 |
| 2024-11-05 | -1.87 |
| 2024-11-04 | -1.87 |
| 2024-11-01 | -1.92 |
| 2024-10-31 | -1.89 |
| 2024-10-30 | -1.99 |
| 2024-10-29 | -1.97 |
| 2024-10-28 | -1.92 |
| 2024-10-25 | -2.08 |
| 2024-10-24 | -2.22 |
| 2024-10-23 | -2.25 |
| 2024-10-22 | -2.30 |
| 2024-10-21 | -2.25 |
| 2024-10-18 | -2.46 |
| 2024-10-17 | -2.16 |
| 2024-10-16 | -2.23 |
| 2024-10-15 | -2.18 |
| 2024-10-14 | -2.42 |
| 2024-10-11 | -2.60 |
| 2024-10-10 | -2.49 |
| 2024-10-09 | -2.53 |
| 2024-10-08 | -2.53 |
| 2024-10-07 | -2.67 |